Intratumoral Leptin Expression and Tissue-Derived LEP rs2167270 Genotype Are Associated with Adverse Pathological Features and Substantial Prognosis in Sudanese Bladder Carcinoma
Bladder carcinoma shows marked pathological and molecular heterogeneity, and tissue-based molecular markers may help identify tumors with aggressive pathological features. In African populations, including Sudan, molecular pathology data on bladder carcinoma remain limited. This study assessed whether intratumoral leptin expression and tissue-derived LEP rs2167270 genotype were associated with histological grade, pathological pT category, muscle invasion, and lymphovascular invasion in Sudanese bladder carcinoma. This retrospective, multicenter, tissue-based study included 153 formalin-fixed, paraffin-embedded bladder carcinoma specimens from four Sudanese institutions. Leptin expression was evaluated by immunohistochemistry and classified using the immunoreactive score. LEP rs2167270 was genotyped by PCR-RFLP using amplifiable FFPE tumor DNA. Assay reliability was evaluated by repeat genotyping and Sanger sequencing. The cohort was predominantly male (120/153, 78.4%), and urothelial carcinoma was the main tumor type (136/153, 88.9%). High-grade tumors were found in 49/136 urothelial carcinomas (36.0%). Muscle invasion was found in 54/149 tumors (36.2%), and lymphovascular invasion was present in 56/149 tumors (37.6%). Moderate-to-strong leptin immunoreactivity was more frequent in high-grade than low-grade tumors (61.2% vs 32.2%; p = 0.004), T2-or-higher than Ta tumors (64.8% vs 32.7%; p = 0.003), muscle-invasive than non-muscle-invasive tumors (64.8% vs 30.5%; p < 0.001), and lymphovascular invasion-positive tumors (64.3% vs 30.1%; p < 0.001). Valid tissue-derived LEP rs2167270 genotypes were obtained in 127 cases. The GG genotype was more frequent with stronger leptin staining (p = 0.005) and showed distributional differences by grade, pT category, muscle invasion, and lymphovascular invasion; however, the pT-category pattern did not show a clear stepwise increase in GG frequency with increasing pT category. PCR-RFLP was concordant with Sanger sequencing in 30 cases. Higher intratumoral leptin expression and tissue-derived LEP rs2167270 GG genotype were associated with adverse pathological features. Studies with matched normal DNA, larger African cohorts, clinical follow-up, and functional validation are needed to determine whether the tissue-derived genotype reflects germline variation, biological relevance, and prognostic value.
References
[1]
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: ACancerJournalforClinicians, 74, 229-263. https://doi.org/10.3322/caac.21834
[2]
Lobo, N., Afferi, L., Moschini, M., Mostafid, H., Porten, S., Psutka, S.P., et al. (2022) Epidemiology, Screening, and Prevention of Bladder Cancer. EuropeanUrologyOncology, 5, 628-639. https://doi.org/10.1016/j.euo.2022.10.003
van der Heijden, A.G., Bruins, H.M., Carrion, A., Cathomas, R., Compérat, E., Dimitropoulos, K., et al. (2025) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines. EuropeanUrology, 87, 582-600. https://doi.org/10.1016/j.eururo.2025.02.019
[5]
Olislagers, M., de Jong, F.C., Rutten, V.C., Boormans, J.L., Mahmoudi, T. and Zuiverloon, T.C.M. (2025) Molecular Biomarkers of Progression in Non-Muscle-Invasive Bladder Cancer—Beyond Conventional Risk Stratification. NatureReviewsUrology, 22, 75-91. https://doi.org/10.1038/s41585-024-00914-7
[6]
Leyderman, M., Chandrasekar, T., Grivas, P., Li, R., Bhat, S., Basnet, A., et al. (2025) Metastasis Development in Non-Muscle-Invasive Bladder Cancer. NatureReviewsUrology, 22, 375-386. https://doi.org/10.1038/s41585-024-00963-y
[7]
Maas, M., Todenh?fer, T. and Black, P.C. (2023) Urine Biomarkers in Bladder Cancer—Current Status and Future Perspectives. NatureReviewsUrology, 20, 597-614. https://doi.org/10.1038/s41585-023-00773-8
[8]
Modak, S., Aktar, T., Majumder, D., Singha, A.K. and Maiti, D. (2025) A Systematic Review on Leptin’s Role in Defining Cancer: Special Emphasis on Immunomodulation, Inflammation, and Therapeutic Interventions. Genes&Immunity, 26, 266-286. https://doi.org/10.1038/s41435-025-00333-7
[9]
Kounatidis, D., Vallianou, N.G., Karampela, I., Grivakou, E. and Dalamaga, M. (2025) The Intricate Role of Adipokines in Cancer-Related Signaling and the Tumor Microenvironment: Insights for Future Research. SeminarsinCancerBiology, 113, 130-150. https://doi.org/10.1016/j.semcancer.2025.05.013
[10]
Khabaz, M.N., Qureshi, I.A. and Al-Maghrabi, J.A. (2021) Leptin Expression Is Substantially Correlated with Prognosis of Urinary Bladder Carcinoma. LibyanJournalofMedicine, 16, Article ID: 1949798. https://doi.org/10.1080/19932820.2021.1949798
[11]
Kashiwagi, E., Abe, T., Kinoshita, F., Ushijima, M., Masaoka, H., Shiota, M., Netto, G.J., Eto, M. and Miyamoto, H. (2020) The Role of Adipocytokines and Their Receptors in Bladder Cancer: Expression of Adiponectin or Leptin Is an Independent Prognosticator. American Journal of Translational Research, 12, 3033-3045.
[12]
Mao, F., Niu, X., Gu, S., Ji, L., Wei, B. and Wang, H. (2020) Investigation of Leptin G19A Polymorphism with Bladder Cancer Risk: A Case-Control Study. JournalofClinicalLaboratoryAnalysis, 34, e23351. https://doi.org/10.1002/jcla.23351
[13]
Lenis, A.T., Lec, P.M., Chamie, K. and Mshs, M. (2020) Bladder Cancer. JAMA, 324, 1980-1991. https://doi.org/10.1001/jama.2020.17598
[14]
Knowles, M.A. and Hurst, C.D. (2015) Molecular Biology of Bladder Cancer: New Insights into Pathogenesis and Clinical Diversity. NatureReviewsCancer, 15, 25-41. https://doi.org/10.1038/nrc3817
[15]
Ahangar, M., Mahjoubi, F. and Mowla, S.J. (2024) Bladder Cancer Biomarkers: Current Approaches and Future Directions. FrontiersinOncology, 14, Article 1453278. https://doi.org/10.3389/fonc.2024.1453278
[16]
Caruso, A., Gelsomino, L., Panza, S., Accattatis, F.M., Naimo, G.D., Barone, I., et al. (2023) Leptin: A Heavyweight Player in Obesity-Related Cancers. Biomolecules, 13, Article 1084. https://doi.org/10.3390/biom13071084
[17]
Bocian-Jastrz?bska, A., Malczewska-Herman, A. and Kos-Kud?a, B. (2023) Role of Leptin and Adiponectin in Carcinogenesis. Cancers, 15, Article 4250. https://doi.org/10.3390/cancers15174250
[18]
Ibrahim, A., Khalid, R., Mohager, S. and Fadl-Elmula, I. (2022) Clinical Characteristics of Urinary Bladder Cancer in the Sudan; Evidence of Pathoetiology Changes. The Gulf Journal of Oncology, 1, 16-20.
[19]
Botelho, M.C., Machado, J.C. and Correia da Costa, J.M. (2010) Schistosomahaematobium and Bladder Cancer: What Lies Beneath? Virulence, 1, 84-87. https://doi.org/10.4161/viru.1.2.10487
[20]
Adeloye, D., Harhay, M.O., Ayepola, O.O., Dos Santos, J.P., David, R.A., Ogunlana, O.O., et al. (2019) Estimate of the Incidence of Bladder Cancer in Africa: A Systematic Review and Bayesian Meta-Analysis. InternationalJournalofUrology, 26, 102-112. https://doi.org/10.1111/iju.13824
[21]
Jonosky, J., Adam, A. and Wadee, R. (2025) A Histopathological Snapshot of Bladder Cancer: A Johannesburg Experience of 1480 Histopathology Reports. WorldJournalofUrology, 43, Article No. 159. https://doi.org/10.1007/s00345-025-05540-5
[22]
Obi Anselm, O. and Ogolo Donald, E. (2021) Cancer of the Bladder in South East Nigeria: Epidemiological Patterns in a Low Resource Region. InternationalJournalofSurgeryResearchandPractice, 8. https://doi.org/10.23937/2378-3397/1410131
[23]
Kamel, H.F.M., Nassir, A.M. and Al Refai, A.A. (2020) Assessment of Expression Levels of Leptin and Leptin Receptor as Potential Biomarkers for Risk of Prostate Cancer Development and Aggressiveness. CancerMedicine, 9, 5687-5696. https://doi.org/10.1002/cam4.3082
[24]
Yang, J., Zhong, Z., Tang, W. and Chen, J. (2019) Leptin rs2167270 G > A (G19A) Polymorphism May Decrease the Risk of Cancer: A Case-Control Study and Meta-Analysis Involving 19 989 Subjects. JournalofCellularBiochemistry, 120, 10998-11007. https://doi.org/10.1002/jcb.28378
[25]
Zhang, A., Wang, S., Zhang, F., Li, W., Li, Q. and Liu, X. (2021) The Prognosis of Leptin rs2167270 G > A (G19A) Polymorphism in the Risk of Cancer: A Meta-Analysis. FrontiersinOncology, 11, Article 754162. https://doi.org/10.3389/fonc.2021.754162
[26]
Saxena, N.K., Sharma, D., Ding, X., Lin, S., Marra, F., Merlin, D., et al. (2007) Concomitant Activation of the JAK/STAT, PI3K/AKT, and ERK Signaling Is Involved in Leptin-Mediated Promotion of Invasion and Migration of Hepatocellular Carcinoma Cells. CancerResearch, 67, 2497-2507. https://doi.org/10.1158/0008-5472.can-06-3075
[27]
Shen, L., Zhang, C., Cui, K., Liang, X., Zhu, G. and Hong, L. (2024) Leptin Secreted by Adipocytes Promotes EMT Transition and Endometrial Cancer Progression via the JAK2/STAT3 Signalling Pathway. Adipocyte, 13, Article ID: 2293273. https://doi.org/10.1080/21623945.2023.2293273
[28]
Herrera-Vargas, A.K., García-Rodríguez, E., Olea-Flores, M., Mendoza-Catalán, M.A., Flores-Alfaro, E. and Navarro-Tito, N. (2021) Pro-Angiogenic Activity and Vasculogenic Mimicry in the Tumor Microenvironment by Leptin in Cancer. Cytokine&GrowthFactorReviews, 62, 23-41. https://doi.org/10.1016/j.cytogfr.2021.10.006
[29]
Lagarde, C.B., Thapa, K., Cullen, N.M., Hawes, M.L., Salim, K., Benz, M.C., et al. (2024) Obesity and Leptin in Breast Cancer Angiogenesis. FrontiersinEndocrinology, 15, Article 1465727. https://doi.org/10.3389/fendo.2024.1465727
[30]
Alfaqih, M.A., Elsalem, L., Nusier, M., Mhedat, K., Khader, Y. and Ababneh, E. (2023) Serum Leptin Receptor and the rs1137101 Variant of the LEPR Gene Are Associated with Bladder Cancer. Biomolecules, 13, Article 1498. https://doi.org/10.3390/biom13101498